1-855-378-42281-855-378-4228
One of the outpatient treatment options for individuals in Congress who are struggling with opioid abuse and addiction is opioid maintenance therapy. Licensed facilities and doctors are authorized to dispense certain meds to opioid addicted individuals, many that are opioids themselves and are addictive. In low enough amounts however, the client doesn't experience high feelings and also does not experience severe cravings and is not in opioid withdrawal. Methadone is the first drug administered for this sole purpose, but there are other options currently to choose from.
Methadone is an opiate and is meant to be taken at an out-patient medical center certified to dispense the drug, that is taken daily as a pill or liquid. The price of the med is about $150 a month. Buprenorphine is also an opioid based med, and is a pill often taken every other day. But unlike Methadone which is only be given in highly well-regulated medical centers, Buprenorphine can be and is prescribed and administered in doctor's offices. The cost monthly of buprenorphine is approximately $300.00 /month for the generic version of the drug. There is also a version of buprenorphine that contains the ingredient naloxone, which is a med which blocks the effects of opioids. An individual consuming this version of the drug, also known as Suboxone, would find it harder to get high from opioids if they relapsed while taking the drug. It is also taken on a daily basis, and is priced approximately $450 a month. Naltrexone is another medication used in opioid maintenance therapy, but unlike the other medications mentioned here it is an opioid blocker and is not an opiate. A person has the choice to take this medication as a monthly shot, which is called Vivitrol. As an opioid blocker, the drug prevents someone from getting high from opioids, and therefore lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 /month.
For All Drug and Alcohol Treatment Centers In Congress, Click Here.
